These nanoparticles induced strong peptide-specific CD8+ T cell responses and anti-tumour activity in a B16.F10 melanoma model, and in PBMCs from healthy donors and melanoma patients, induced proliferative CD8+ T cell responses against the tumour antigen Melan-A. The gene discussed is MLANA; the disease is melanoma.